Project Grant K08HL177422
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$152K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This $737,111 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of low-density lipoprotein (LDL) in hemostasis, or the process of blood clotting, for individuals with hemophilia A. The overarching objective is to test the hypothesis that LDL improves hemostasis by increasing platelet adhesion, accelerating clotting time, increasing clot strength, and...
This federal Project Grant award of $1,993,215 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program is supporting research by Versiti Wisconsin, Inc. and its sub-awardees, the University of North Carolina at Chapel Hill and the Medical College of Wisconsin, to develop an RNA therapy against excess fibrinogen for controlling thromboembolism after polytrauma. The key research objectives include: Determining the minimum...
This $685,884 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of the C1 inhibitor protein in regulating coagulation and thrombosis, with the goal of identifying new therapeutic approaches for preventing venous thromboembolism. The research aims to: 1) Evaluate the molecular mechanisms by which C1 inhibitor regulates coagulation and venous thrombosis in mice, 2) Assess the impact of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $3,007,209 to The University of Texas Health Science Center at Tyler (UTHSCT) to conduct research on the role of GAB2-MALT1-mediated cell signaling in venous thrombogenesis. The research aims to elucidate the molecular mechanisms by which the signaling adapter protein GAB2 mediates thromboinflammatory signaling in endothelial cells,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,180,494 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the Masonic Medical Research Lab in Utica, NY. The grant supports research to utilize a novel murine model of pulmonary embolism (PE) to investigate the inflammatory and fibrotic responses, as well as to evaluate fibrin changes and downstream effects on PE-induced inflammation and pulmonary fibrosis. The research aims to provide a...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $718,854 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Versiti Wisconsin, Inc., a non-profit blood center and research organization located in Milwaukee, Wisconsin. The grant supports research to elucidate the cellular mechanisms governing the non-conventional signaling function of the A5B1 integrin in the formation of tunneling nanotubes (TNTs) and inflammatory...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $391,250.00 to Emory University to investigate fibrinogen as a key mediator of COVID-19-associated coagulopathy. The primary objectives are to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity, as well as the role of a specific fibrinogen isoform (Gc fibrinogen) in altering blood biophysical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,276,908 to Bloodworks, a nonprofit research organization in Seattle, to conduct molecular and translational studies on hematologic disorders. The key objectives are to investigate the mechanisms of disease in von Willebrand disease and sickle cell disease, which both involve the von Willebrand factor protein. The research aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research focused on investigating short inhibitory RNAs (siRNAs) to modulate megakaryocyte and platelet function. The key objectives of this $552,413 award, with a performance period from April 1, 2025 to January 31, 2029, are to: 1) investigate in vivo siRNA-mediated knockdown of the P2Y12 receptor in megakaryocytes...